Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of MAX-40279 Given Orally to Subjects With Acute Myelogenous Leukemia (AML)

NCT03412292 is registered in ClinicalTrials.gov with Maxinovel Pty., Ltd. as lead sponsor.

NCT NCT03412292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03412292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of MAX-40279 Given Orally to Subjects With Acute Myelogenous Leukemia (AML)
Lead sponsor
Maxinovel Pty., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
August 1, 2018
Completion date
December 1, 2022
Enrollment
30 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia (aml)